{"id":47928,"date":"2026-05-06T08:46:06","date_gmt":"2026-05-06T06:46:06","guid":{"rendered":"https:\/\/semaxpolska.com\/?p=47928"},"modified":"2026-05-12T08:59:09","modified_gmt":"2026-05-12T06:59:09","slug":"ako-funguje-tesamorelin","status":"publish","type":"post","link":"https:\/\/bioevidencehub.com\/sk\/jak-dziala-tesamorelin\/","title":{"rendered":"\u010co je Tesamorelin a ako funguje?"},"content":{"rendered":"<p data-start=\"40\" data-end=\"755\">Tesamorelin je syntetick\u00fd peptid, ktor\u00fd pom\u00e1ha telu prirodzene zvy\u0161ova\u0165 produkciu a uvo\u013e\u0148ovanie rastov\u00e9ho horm\u00f3nu (GH). Je navrhnut\u00fd tak, aby napodob\u0148oval \u00fa\u010dinok horm\u00f3nu uvo\u013e\u0148uj\u00faceho rastov\u00fd horm\u00f3n (GHRH), \u010do je prirodzen\u00fd horm\u00f3n produkovan\u00fd v mozgu, ktor\u00fd vysiela sign\u00e1l hypof\u00fdze, aby uvo\u013enila GH. Tesamorelin je najviac zn\u00e1my svoj\u00edm \u00fa\u010dinkom na zn\u00ed\u017eenie viscer\u00e1lneho tukov\u00e9ho tkaniva (VAT), \u010do je hlbok\u00fd bru\u0161n\u00fd tuk hromadiaci sa okolo vn\u00fatorn\u00fdch org\u00e1nov. Tento typ tuku je silne spojen\u00fd s metabolick\u00fdmi probl\u00e9mami a lipodystrofiou s\u00favisiacou s HIV, \u010do je porucha distrib\u00facie telesn\u00e9ho tuku, ktor\u00e1 sa objavuje po\u010das antiretrov\u00edrusovej terapie.<\/p>\n<p data-start=\"757\" data-end=\"1279\">Tesamorelin \u00fa\u010dinkuje v\u00e4zbou na receptory GHRH v hypof\u00fdze. To stimuluje telo k uvo\u013e\u0148ovaniu vlastn\u00e9ho rastov\u00e9ho horm\u00f3nu v prirodzen\u00fdch pulzoch, \u010do n\u00e1sledne zvy\u0161uje hladinu inzul\u00ednu podobn\u00e9ho rastov\u00e9ho faktora-1 (IGF-1). IGF-1 je horm\u00f3n spojen\u00fd s metabolizmom, regener\u00e1ciou tkan\u00edv, udr\u017eiavan\u00edm svalovej hmoty a rastom buniek. Na rozdiel od priamych injekci\u00ed rastov\u00e9ho horm\u00f3nu, tesamorelin nenahr\u00e1dza GH zvonku. Namiesto toho stimuluje prirodzen\u00fd syst\u00e9m rastov\u00e9ho horm\u00f3nu tela.<\/p>\n<p data-start=\"1281\" data-end=\"2153\">V\u00e4\u010d\u0161ina \u0161t\u00fadi\u00ed zameran\u00fdch na tesamorel\u00edn sa s\u00fastredila na osoby s HIV, u ktor\u00fdch doch\u00e1dza k nadmern\u00e9mu nahromadeniu bru\u0161n\u00e9ho tuku po\u010das antiretrov\u00edrusovej lie\u010dby. Klinick\u00e9 \u0161t\u00fadie opakovane preuk\u00e1zali, \u017ee tesamorelin m\u00f4\u017ee v\u00fdrazne zn\u00ed\u017ei\u0165 mno\u017estvo viscer\u00e1lneho tuku, obvod p\u00e1sa a tuk v oblasti trupu, pri\u010dom zvy\u010dajne zachov\u00e1va podko\u017en\u00fd tuk, teda tuk nach\u00e1dzaj\u00faci sa pod ko\u017eou, ako aj tuk v ramen\u00e1ch a noh\u00e1ch. V placebom kontrolovan\u00fdch \u0161t\u00fadi\u00e1ch trvaj\u00facich 6 a\u017e 12 mesiacov sa \u010dasto pozorovalo zn\u00ed\u017eenie viscer\u00e1lneho tuku o pribli\u017ene 10\u201318%. Vedci tie\u017e zaznamenali zlep\u0161enie vn\u00edmania vlastn\u00e9ho vzh\u013eadu a niektor\u00fdch ukazovate\u013eov metabolick\u00e9ho zdravia. Z\u00e1rove\u0148 \u0161t\u00fadie uk\u00e1zali, \u017ee po vysaden\u00ed tesamorel\u00ednu sa viscer\u00e1lny tuk postupne vr\u00e1til, \u010do nazna\u010duje, \u017ee udr\u017eanie \u00fa\u010dinkov m\u00f4\u017ee vy\u017eadova\u0165 pokra\u010dovanie lie\u010dby.<\/p>\n<p data-start=\"2155\" data-end=\"2793\">Tesamorelin bol tie\u017e sk\u00faman\u00fd pre svoje \u00fa\u010dinky na stlstnutie pe\u010dene a metabolick\u00e9 zdravie. U os\u00f4b s NAFLD spojen\u00fdm s HIV \u0161t\u00fadie uk\u00e1zali zn\u00ed\u017eenie mno\u017estva tuku v pe\u010deni spolu so zlep\u0161en\u00edm metabolick\u00fdch markerov s\u00favisiacich s funkciou tohto org\u00e1nu. D\u00f4le\u017eit\u00e9 je, \u017ee tieto \u00fa\u010dinky boli pozorovan\u00e9 bez v\u00fdznamn\u00e9ho zhor\u0161enia kontroly hladiny cukru v krvi. Vedci tie\u017e analyzovali potenci\u00e1lny vplyv tesamorelinu na z\u00e1pal, metabolizmus tukov, kvalitu tukov\u00e9ho tkaniva, zdrav\u00e9 starnutie a funkcie mozgu vzh\u013eadom na jeho vplyv na dr\u00e1hy rastov\u00e9ho horm\u00f3nu a IGF-1 spojen\u00e9 s regener\u00e1ciou a metabolizmom.<\/p>\n<p data-start=\"2795\" data-end=\"3258\">Tesamorelin je pova\u017eovan\u00fd za peptid, preto\u017ee sa sklad\u00e1 z aminokysel\u00edn usporiadan\u00fdch sp\u00f4sobom imituj\u00facim prirodzen\u00fd \u013eudsk\u00fd GHRH. Je to modifikovan\u00e1 a stabilnej\u0161ia verzia prirodzen\u00e9ho GHRH, navrhnut\u00e1 tak, aby bola odolnej\u0161ia vo\u010di degrad\u00e1cii enz\u00fdmami v tele. V\u010faka tomu tesamorelin zost\u00e1va akt\u00edvny dlh\u0161ie a \u00fa\u010dinnej\u0161ie stimuluje uvo\u013e\u0148ovanie rastov\u00e9ho horm\u00f3nu ako prirodzen\u00fd GHRH, pri\u010dom si zachov\u00e1va prirodzenej\u0161\u00ed vzor sekr\u00e9cie horm\u00f3nov.<\/p>\n<p data-start=\"3260\" data-end=\"3786\">V\u00fdskumy tie\u017e nazna\u010duj\u00fa, \u017ee tesamorel\u00edn m\u00f4\u017ee zlep\u0161i\u0165 zlo\u017eenie tela zn\u00ed\u017een\u00edm mno\u017estva viscer\u00e1lneho tuku pri s\u00fa\u010dasnom zv\u00fd\u0161en\u00ed beztukovej telesnej hmoty. Nieko\u013eko klinick\u00fdch \u0161t\u00fadi\u00ed a vedeck\u00fdch preh\u013eadov preuk\u00e1zalo zn\u00ed\u017eenie obvodu p\u00e1sa, mno\u017estva telesn\u00e9ho tuku a pe\u010de\u0148ov\u00e9ho tuku spolu so zv\u00fd\u0161en\u00edm svalovej hmoty a hlad\u00edn IGF-1. Tieto zmeny sa zvy\u010dajne dosiahli bez z\u00e1va\u017en\u00fdch ved\u013eaj\u0161\u00edch \u00fa\u010dinkov alebo v\u00e1\u017enych hormon\u00e1lnych nerovnov\u00e1h, \u010d\u00edm sa tesamorel\u00edn odli\u0161uje od priamej lie\u010dby rastov\u00fdm horm\u00f3nom.<\/p>\n<p data-start=\"3788\" data-end=\"4238\">Hoci tesamorelin je prim\u00e1rne sp\u00e1jan\u00fd s lipodystrofiou s\u00favisiacou s HIV, vedeck\u00fd z\u00e1ujem sa roz\u0161\u00edril aj na in\u00e9 oblasti, ako s\u00fa metabolick\u00e9 poruchy s\u00favisiace s obezitou, stukovatenie pe\u010dene, zdrav\u00e9 starnutie, kognit\u00edvne funkcie a biol\u00f3gia tukov\u00e9ho tkaniva. Vedcov obzvl\u00e1\u0161\u0165 zauj\u00edma vplyv anal\u00f3gov GHRH na viscer\u00e1lny tuk v bru\u0161nej dutine, funkciu mitochondri\u00ed, z\u00e1paly, metabolizmus a mechanizmy regener\u00e1cie tkan\u00edv.<\/p>\n<h3 data-section-id=\"12vzxnw\" data-start=\"4240\" data-end=\"4256\">Zrieknutie sa zodpovednosti<\/h3>\n<p data-start=\"4258\" data-end=\"4818\">Inform\u00e1cie t\u00fdkaj\u00face sa tesamorelinu s\u00fa v\u00fdlu\u010dne vzdel\u00e1vacie a vedeck\u00e9. Tesamorelin je peptid na lek\u00e1rsky predpis, schv\u00e1len\u00fd pre ur\u010dit\u00e9 lek\u00e1rske pou\u017eitie, pri\u010dom sa na\u010falej sk\u00famaj\u00fa jeho \u0161ir\u0161ie \u00fa\u010dinky. Tu op\u00edsan\u00e9 \u0161t\u00fadie, mechanizmy a v\u00fdsledky vych\u00e1dzaj\u00fa z publikovan\u00fdch vedeck\u00fdch \u00fadajov a nemali by sa pova\u017eova\u0165 za lek\u00e1rsku radu, diagn\u00f3zu ani lie\u010debn\u00e9 odpor\u00fa\u010danie. Ka\u017ed\u00fd, kto zva\u017euje hormon\u00e1lnu terapiu alebo intervencie zalo\u017een\u00e9 na peptidoch, by sa mal poradi\u0165 s kvalifikovan\u00fdm zdravotn\u00edckym pracovn\u00edkom.<\/p>\n<h2 data-section-id=\"xwtf3n\" data-start=\"4820\" data-end=\"4872\">Ako funguje Tesamorelin?<\/h2>\n<p data-start=\"4874\" data-end=\"5473\">Tesamorelin p\u00f4sob\u00ed napodob\u0148ovan\u00edm \u00fa\u010dinkov prirodzen\u00e9ho horm\u00f3nu uvo\u013e\u0148uj\u00faceho rastov\u00fd horm\u00f3n (GHRH), ktor\u00fd je zodpovedn\u00fd za signaliz\u00e1ciu hypof\u00fdzy, aby uvo\u013enila rastov\u00fd horm\u00f3n (GH). Po podan\u00ed sa tesamorelin via\u017ee na receptory GHRH na bunk\u00e1ch hypof\u00fdzy naz\u00fdvan\u00fdch somatotrofy. To potom sp\u00f4sobuje, \u017ee telo uvo\u013e\u0148uje svoj vlastn\u00fd rastov\u00fd horm\u00f3n v prirodzen\u00fdch pulzoch. Ako hladina GH st\u00fapa, pe\u010de\u0148 za\u010dne produkova\u0165 viac inzul\u00ednov\u00e9ho rastov\u00e9ho faktora-1 (IGF-1), ktor\u00fd je zodpovedn\u00fd za mnoh\u00e9 z metabolick\u00fdch \u00fa\u010dinkov a zmien zlo\u017eenia tela spojen\u00fdch s tesamorelinom.<\/p>\n<p data-start=\"5475\" data-end=\"5944\">Najd\u00f4le\u017eitej\u0161ou vlastnos\u0165ou mechanizmu \u00fa\u010dinku tesamorel\u00ednu je, \u017ee posil\u0148uje prirodzen\u00fd syst\u00e9m rastov\u00e9ho horm\u00f3nu tela namiesto priameho nahradenia rastov\u00e9ho horm\u00f3nu. Toto je d\u00f4le\u017eit\u00e9, preto\u017ee to umo\u017e\u0148uje zachova\u0165 prirodzen\u00fd mechanizmus sp\u00e4tnej v\u00e4zby horm\u00f3nov. Na rozdiel od priamych injekci\u00ed GH, tesamorel\u00edn udr\u017eiava pulzatile sekr\u00e9ciu rastov\u00e9ho horm\u00f3nu, \u010do znamen\u00e1, \u017ee GH sa uvo\u013e\u0148uje v rytmick\u00fdch v\u00fdronoch podobn\u00fdch prirodzenej fyziol\u00f3gii.<\/p>\n<p data-start=\"5946\" data-end=\"6669\">Metabolicky tesamorelin pom\u00e1ha rozklada\u0165 ulo\u017een\u00fd tuk, najm\u00e4 viscer\u00e1lny tuk nach\u00e1dzaj\u00faci sa hlboko v bru\u0161nej dutine. Rastov\u00fd horm\u00f3n aktivuje enz\u00fdmy zapojen\u00e9 do lipol\u00fdzy, \u010do je proces rozkladu triglyceridov nahromaden\u00fdch v tukov\u00fdch bunk\u00e1ch. Viscer\u00e1lny tuk je obzvl\u00e1\u0161\u0165 citliv\u00fd na rastov\u00fd horm\u00f3n, preto\u017ee obsahuje ve\u013ea receptorov reaguj\u00facich na GH a vyzna\u010duje sa vysokou metabolickou aktivitou. Z tohto d\u00f4vodu tesamorelin p\u00f4sob\u00ed prim\u00e1rne na hlbok\u00fd bru\u0161n\u00fd tuk, pri\u010dom \u010dasto zachov\u00e1va podko\u017en\u00fd tuk. Klinick\u00e9 \u0161t\u00fadie d\u00f4sledne preuk\u00e1zali zn\u00ed\u017eenie viscer\u00e1lneho tuku, obvodu p\u00e1sa a tuku v oblasti trupu po\u010das lie\u010dby tesamorelinom.<\/p>\n<p data-start=\"6671\" data-end=\"7304\">\u010eal\u0161ou d\u00f4le\u017eitou s\u00fa\u010das\u0165ou \u00fa\u010dinku tesamorelinu je zv\u00fd\u0161enie hladiny IGF-1. Tento horm\u00f3n sa produkuje preva\u017ene v pe\u010deni po stimul\u00e1cii rastov\u00fdm horm\u00f3nom a podporuje udr\u017eanie svalovej hmoty, regener\u00e1ciu tkan\u00edv, synt\u00e9zu bielkov\u00edn a metabolizmus. Vy\u0161\u0161ie hladiny IGF-1 s\u00fa spojen\u00e9 so zv\u00fd\u0161en\u00edm beztukovej telesnej hmoty, lep\u0161\u00edmi regenera\u010dn\u00fdmi procesmi a zlep\u0161en\u00edm bunkovej opravy. Niektor\u00e9 \u0161t\u00fadie tie\u017e nazna\u010duj\u00fa, \u017ee IGF-1 m\u00f4\u017ee podporova\u0165 zdravie mozgu, funkciu mitochondri\u00ed, protiz\u00e1palov\u00fa signaliz\u00e1ciu a ochranu nervov\u00fdch buniek, preto tesamorelin vzbudil z\u00e1ujem v \u0161t\u00fadi\u00e1ch starnutia a kognit\u00edvnych funkci\u00ed.<\/p>\n<p data-start=\"7306\" data-end=\"7781\">Tesamorelin m\u00f4\u017ee tie\u017e zlep\u0161ova\u0165 zdravie pe\u010dene a metabolizmus tukov. V \u0161t\u00fadi\u00e1ch o stukovaten\u00ed pe\u010dene s\u00favisiacom s HIV tesamorelin zn\u00ed\u017eil mno\u017estvo tuku hromadiaceho sa v pe\u010deni. Vedci sa domnievaj\u00fa, \u017ee to m\u00f4\u017ee by\u0165 sp\u00f4soben\u00e9 nieko\u013ek\u00fdmi mechanizmami, vr\u00e1tane zv\u00fd\u0161en\u00e9ho spa\u013eovania tukov, zn\u00ed\u017eenej produkcie nov\u00e9ho tuku v pe\u010deni, zlep\u0161en\u00e9ho rozlo\u017eenia tuku v tele a obmedzenia transportu mastn\u00fdch kysel\u00edn z bru\u0161n\u00e9ho tuku do pe\u010dene.<\/p>\n<p data-start=\"7783\" data-end=\"8257\">\u010eal\u0161\u00ed d\u00f4le\u017eit\u00fd efekt sa t\u00fdka z\u00e1palu a kvality tukov\u00e9ho tkaniva. Nadbytok viscer\u00e1lneho tuku je silne spojen\u00fd s chronick\u00fdm z\u00e1palom n\u00edzkej intenzity, inzul\u00ednovou rezistenciou a metabolick\u00fdmi poruchami. Zni\u017eovan\u00edm mno\u017estva viscer\u00e1lneho tuku m\u00f4\u017ee tesamorelin nepriamo zlep\u0161i\u0165 z\u00e1palov\u00e9 a metabolick\u00e9 markery. V niektor\u00fdch \u0161t\u00fadi\u00e1ch bola po\u010das lie\u010dby pozorovan\u00e1 zlep\u0161en\u00e1 hladina triglyceridov, adiponekt\u00ednu a in\u00fdch metabolick\u00fdch ukazovate\u013eov.<\/p>\n<p data-start=\"8259\" data-end=\"8968\">Tesamorelin bol sk\u00faman\u00fd aj pre mo\u017en\u00fd vplyv na funkcie mozgu, ke\u010f\u017ee rastov\u00fd horm\u00f3n a IGF-1 ovplyv\u0148uj\u00fa mnoh\u00e9 neurologick\u00e9 procesy. IGF-1 m\u00f4\u017ee prekro\u010di\u0165 bari\u00e9ru krv-mozog a podie\u013ea sa na tvorbe nov\u00fdch neur\u00f3nov, podpore pre\u017eitia nervov\u00fdch buniek, zlep\u0161en\u00ed komunik\u00e1cie medzi neur\u00f3nmi a zn\u00ed\u017een\u00ed oxida\u010dn\u00e9ho stresu. Vedci analyzovali, \u010di zn\u00ed\u017eenie bru\u0161n\u00e9ho tuku a zv\u00fd\u0161enie IGF-1 m\u00f4\u017ee zlep\u0161i\u0165 kognit\u00edvne funkcie u os\u00f4b s neurokognit\u00edvnymi poruchami s\u00favisiacimi s HIV. Hoci niektor\u00e9 \u0161t\u00fadie uk\u00e1zali zv\u00fd\u0161enie hladiny IGF-1 a zn\u00ed\u017eenie obvodu p\u00e1sa, zlep\u0161enie kognit\u00edvnych funkci\u00ed bolo zvy\u010dajne mierne a nie v\u017edy dosahovalo \u0161tatistick\u00fa v\u00fdznamnos\u0165.<\/p>\n<p data-start=\"8970\" data-end=\"9358\">Z h\u013eadiska n\u00e1vrhu liekov bol tesamorelin vytvoren\u00fd ako stabilizovan\u00e1 verzia GHRH. Prirodzen\u00fd GHRH sa v tele ve\u013emi r\u00fdchlo rozklad\u00e1, \u010do obmedzuje jeho pou\u017eitie. Tesamorelin obsahuje \u0161truktur\u00e1lne zmeny, ktor\u00e9 zvy\u0161uj\u00fa jeho odolnos\u0165 vo\u010di enzymatick\u00e9mu rozkladu, \u010d\u00edm zost\u00e1va dlh\u0161ie akt\u00edvny a \u00fa\u010dinnej\u0161ie stimuluje uvo\u013e\u0148ovanie rastov\u00e9ho horm\u00f3nu po subkut\u00e1nnom podan\u00ed.<\/p>\n<p data-start=\"9360\" data-end=\"9918\">V\u0161eobecne povedan\u00e9, tesamorelin funguje ako cieln\u00fd peptidov\u00fd liek, ktor\u00fd posil\u0148uje prirodzen\u00fd syst\u00e9m rastov\u00e9ho horm\u00f3nu v tele. Jeho \u00fa\u010dinky zah\u0155\u0148aj\u00fa signaliz\u00e1ciu rastov\u00e9ho horm\u00f3nu, produkciu IGF-1, metabolizmus viscer\u00e1lneho tuku, regul\u00e1ciu tukov v pe\u010deni a dr\u00e1hy regener\u00e1cie tkan\u00edv. T\u00e1to kombin\u00e1cia \u00fa\u010dinkov vysvet\u013euje, pre\u010do bol tesamorelin rozsiahlo \u0161tudovan\u00fd v kontexte zni\u017eovania viscer\u00e1lneho tuku, lipodystrofie s\u00favisiacej s HIV, steat\u00f3zy pe\u010dene, metabolick\u00fdch por\u00fach a in\u00fdch probl\u00e9mov spojen\u00fdch s abnorm\u00e1lnym rozlo\u017een\u00edm telesn\u00e9ho tuku.<\/p>\n<h3 data-section-id=\"12vzxnw\" data-start=\"9920\" data-end=\"9936\">Zrieknutie sa zodpovednosti<\/h3>\n<p data-start=\"9938\" data-end=\"10389\" data-is-last-node=\"\" data-is-only-node=\"\">Toto vysvetlenie mechanizmu \u00fa\u010dinku tesamorelinu je v\u00fdlu\u010dne vzdel\u00e1vacie a vedeck\u00e9. Hoci klinick\u00e9 a predklinick\u00e9 \u0161t\u00fadie analyzovali \u00fa\u010dinky tesamorelinu na signaliz\u00e1ciu rastov\u00e9ho horm\u00f3nu, metabolizmus, zdravie pe\u010dene a zlo\u017eenie tela, v\u00fdskum jeho dlhodobej bezpe\u010dnosti a \u0161ir\u0161\u00edch \u00fa\u010dinkov st\u00e1le prebieha. Tento obsah nepredstavuje lek\u00e1rsku radu a nenahr\u00e1dza konzult\u00e1ciu s licencovan\u00fdm zdravotn\u00edckym pracovn\u00edkom.<\/p>\n<h4>Odkazy<\/h4>\n<ul>\n<li data-start=\"368\" data-end=\"839\"><span style=\"font-size: 10pt;\">Falutz, J., Potvin, D., Mamputu, J.-C., Assaad, H., Zoltowska, M., Michaud, S.-E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., &amp; Grinspoon, S. (2010). \u00da\u010dinky tesamorelinu, faktora uvo\u013e\u0148uj\u00faceho rastov\u00fd horm\u00f3n, u pacientov s HIV s akumul\u00e1ciou bru\u0161n\u00e9ho tuku: Randomizovan\u00e1 platomom kontrolovan\u00e1 \u0161t\u00fadia s pred\u013a\u017een\u00edm bezpe\u010dnosti. <em data-start=\"728\" data-end=\"781\">Journal of Acquired Immune Deficiency Syndromes, 53<\/em>(3), 311\u2013322. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"795\" data-end=\"839\">https:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff<\/a><\/span><\/li>\n<li data-start=\"841\" data-end=\"1144\"><span style=\"font-size: 10pt;\">Ellis, R. J., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R. K., Lee, D., &amp; Sattler, F. S. (2025). \u00da\u010dinky tesamorelinu na neurokognit\u00edvne po\u0161kodenie u os\u00f4b s HIV a bru\u0161nou obezitou. <em data-start=\"1049\" data-end=\"1090\">The Journal of Infectious Diseases, 231<\/em>(5), 1230\u20131238. <a class=\"decorated-link\" href=\"https:\/\/doi.org\/10.1093\/infdis\/jiaf012\" target=\"_new\" rel=\"noopener\" data-start=\"1106\" data-end=\"1144\">https:\/\/doi.org\/10.1093\/infdis\/jiaf012<\/a><\/span><\/li>\n<li data-start=\"1146\" data-end=\"1442\"><span style=\"font-size: 10pt;\">Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S. a kol. (2019). \u00da\u010dinky tesamorelinu na nealkoholick\u00e9 steat\u00f3zy pe\u010dene u HIV: Randomizovan\u00e1, dvojito zaslepen\u00e1, multicentrick\u00e1 \u0161t\u00fadia. <em data-start=\"1361\" data-end=\"1380\">The Lancet HIV, 6<\/em>(12), e821\u2013e830. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"1397\" data-end=\"1442\">https:\/\/doi.org\/10.1016\/S2352-3018(19)30338-8<\/a><\/span><\/li>\n<li data-start=\"1444\" data-end=\"1791\"><span style=\"font-size: 10pt;\">Rahman, F., McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., &amp; Aberg, J. A. (2022). \u00da\u010dinok tesamorelinu u \u013eud\u00ed s HIV s dorzocervik\u00e1lnym tukom alebo bez neho: Post hoc anal\u00fdza f\u00e1zy III dvojito zaslepenej, placebom kontrolovanej \u0161t\u00fadie. <em data-start=\"1695\" data-end=\"1745\">Journal of Clinical and Translational Science, 7<\/em>(1), e40. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"1755\" data-end=\"1791\">https:\/\/doi.org\/10.1017\/cts.2022.515<\/a><\/span><\/li>\n<li data-start=\"1793\" data-end=\"2125\"><span style=\"font-size: 10pt;\">Badran, A. S., Helal, A., Shata, K. S., &amp; Ayesh, H. (2026). Zlo\u017eenie tela, pe\u010de\u0148ov\u00fd tuk, metabolick\u00e9 ukazovatele a bezpe\u010dnostn\u00e9 v\u00fdsledky tesamorelinu, anal\u00f3gu GHRH, pri lipodystrofii spojenej s HIV: Metanal\u00fdza randomizovan\u00fdch kontrolovan\u00fdch \u0161t\u00fadi\u00ed. <em data-start=\"2030\" data-end=\"2072\">Obesity Research &amp; Clinical Practice, 20<\/em>(1), 2\u201312. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"2083\" data-end=\"2125\">https:\/\/doi.org\/10.1016\/j.orcp.2026.01.002<\/a><\/span><\/li>\n<li data-start=\"2254\" data-end=\"2725\"><span style=\"font-size: 10pt;\">Falutz, J., Potvin, D., Mamputu, J.-C., Assaad, H., Zoltowska, M., Michaud, S.-E., Berger, D., Somero, M., Moyle, G., Brown, S., Martorell, C., Turner, R., &amp; Grinspoon, S. (2010). \u00da\u010dinky tesamorelinu, faktora uvo\u013e\u0148uj\u00faceho rastov\u00fd horm\u00f3n, u pacientov s HIV s akumul\u00e1ciou bru\u0161n\u00e9ho tuku: Randomizovan\u00e1 platomom kontrolovan\u00e1 \u0161t\u00fadia s pred\u013a\u017een\u00edm bezpe\u010dnosti. <em data-start=\"2614\" data-end=\"2667\">Journal of Acquired Immune Deficiency Syndromes, 53<\/em>(3), 311\u2013322. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"2681\" data-end=\"2725\">https:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff<\/a><\/span><\/li>\n<li data-start=\"2727\" data-end=\"3030\"><span style=\"font-size: 10pt;\">Ellis, R. J., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R. K., Lee, D., &amp; Sattler, F. S. (2025). \u00da\u010dinky tesamorelinu na neurokognit\u00edvne po\u0161kodenie u os\u00f4b s HIV a bru\u0161nou obezitou. <em data-start=\"2935\" data-end=\"2976\">The Journal of Infectious Diseases, 231<\/em>(5), 1230\u20131238. <a class=\"decorated-link\" href=\"https:\/\/doi.org\/10.1093\/infdis\/jiaf012\" target=\"_new\" rel=\"noopener\" data-start=\"2992\" data-end=\"3030\">https:\/\/doi.org\/10.1093\/infdis\/jiaf012<\/a><\/span><\/li>\n<li data-start=\"3032\" data-end=\"3328\"><span style=\"font-size: 10pt;\">Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S. a kol. (2019). \u00da\u010dinky tesamorelinu na nealkoholick\u00e9 steat\u00f3zy pe\u010dene u HIV: Randomizovan\u00e1, dvojito zaslepen\u00e1, multicentrick\u00e1 \u0161t\u00fadia. <em data-start=\"3247\" data-end=\"3266\">The Lancet HIV, 6<\/em>(12), e821\u2013e830. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"3283\" data-end=\"3328\">https:\/\/doi.org\/10.1016\/S2352-3018(19)30338-8<\/a><\/span><\/li>\n<li data-start=\"3330\" data-end=\"3677\"><span style=\"font-size: 10pt;\">Rahman, F., McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., &amp; Aberg, J. A. (2022). \u00da\u010dinok tesamorelinu u \u013eud\u00ed s HIV s dorzocervik\u00e1lnym tukom alebo bez neho: Post hoc anal\u00fdza f\u00e1zy III dvojito zaslepenej, placebom kontrolovanej \u0161t\u00fadie. <em data-start=\"3581\" data-end=\"3631\">Journal of Clinical and Translational Science, 7<\/em>(1), e40. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"3641\" data-end=\"3677\">https:\/\/doi.org\/10.1017\/cts.2022.515<\/a><\/span><\/li>\n<li data-start=\"3679\" data-end=\"4011\"><span style=\"font-size: 10pt;\">Badran, A. S., Helal, A., Shata, K. S., &amp; Ayesh, H. (2026). Zlo\u017eenie tela, pe\u010de\u0148ov\u00fd tuk, metabolick\u00e9 ukazovatele a bezpe\u010dnostn\u00e9 v\u00fdsledky tesamorelinu, anal\u00f3gu GHRH, pri lipodystrofii spojenej s HIV: Metanal\u00fdza randomizovan\u00fdch kontrolovan\u00fdch \u0161t\u00fadi\u00ed. <em data-start=\"3916\" data-end=\"3958\">Obesity Research &amp; Clinical Practice, 20<\/em>(1), 2\u201312. <a class=\"decorated-link cursor-pointer\" target=\"_new\" rel=\"noopener\" data-start=\"3969\" data-end=\"4011\" data-is-last-node=\"\">https:\/\/doi.org\/10.1016\/j.orcp.2026.01.002<\/a><\/span><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Tesamorel\u00edn je syntetick\u00fd peptid, ktor\u00fd pom\u00e1ha telu prirodzene zvy\u0161ova\u0165 produkciu a uvo\u013e\u0148ovanie rastov\u00e9ho horm\u00f3nu (GH). Bol navrhnut\u00fd tak, aby napodob\u0148oval \u00fa\u010dinok horm\u00f3nu uvo\u013e\u0148uj\u00faceho rastov\u00fd horm\u00f3n (GHRH),...<\/p>","protected":false},"author":7908,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[236],"tags":[],"class_list":["post-47928","post","type-post","status-publish","format-standard","hentry","category-kategoria-tesamorelin","beh-no-thumb"],"_links":{"self":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/posts\/47928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/users\/7908"}],"replies":[{"embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/comments?post=47928"}],"version-history":[{"count":0,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/posts\/47928\/revisions"}],"wp:attachment":[{"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/media?parent=47928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/categories?post=47928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioevidencehub.com\/sk\/wp-json\/wp\/v2\/tags?post=47928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}